AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02443402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin glargine
Description: When regular insulin is discontinued, if needed, insulin glargine will be given once daily. Patients who required continuous insulin infusion at an average rate >2U/h will be transitioned to basal (to be given approx. 4 hours prior to discontinuing the insulin drip) starting at a dose 0.2 U/Kg/d.~Subjects with a BG at 140-200 mg/dL will start glargine at 0.2 U/kg weight per day. And subjects with BG between 201-400 mg/dL will start glargine at 0.2 U/Kg/day~The basal insulin dose will be adjusted as follow:~* If fasting and pre-dinner BG is between 100 - 180 mg/dL in the absence of hypoglycemia the previous day: no change~* If fasting and pre-dinner BG is between 180 - 240 mg/dL in the absence of hypoglycemia: increase glargine by 10% every day~* If fasting and pre-dinner BG is > 241 mg/dL in the absence of hypoglycemia the previous day: increase glargine dose by 20% every day~* If fasting and pre-dinner BG is \< 100 mg/dL in the absence of hypoglycemia: stop glargine
Study NCT02443402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: When regular insulin is discontinued, if needed, insulin glargine will be given once daily. Patients who required continuous insulin infusion at an average rate >2U/h will be transitioned to basal (to be given approx. 4 hours prior to discontinuing the insulin drip) starting at a dose 0.2 U/Kg/d.~Subjects with a BG at 140-200 mg/dL will start glargine at 0.2 U/kg weight per day. And subjects with BG between 201-400 mg/dL will start glargine at 0.2 U/Kg/day~The basal insulin dose will be adjusted as follow:~* If fasting and pre-dinner BG is between 100 - 180 mg/dL in the absence of hypoglycemia the previous day: no change~* If fasting and pre-dinner BG is between 180 - 240 mg/dL in the absence of hypoglycemia: increase glargine by 10% every day~* If fasting and pre-dinner BG is > 241 mg/dL in the absence of hypoglycemia the previous day: increase glargine dose by 20% every day~* If fasting and pre-dinner BG is \< 100 mg/dL in the absence of hypoglycemia: stop glargine
Study NCT02443402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Supplemental insulin (Insulin lispro)
Description: Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG >240 mg/dL will be given.~For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG > 400 mg/dL; 7-9 units of insulin lispro
Study NCT02443402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental insulin (Insulin lispro)
Description: Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG >240 mg/dL will be given.~For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG > 400 mg/dL; 7-9 units of insulin lispro
Study NCT02443402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Supplemental insulin (Insulin aspart)
Description: Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG >240 mg/dL will be given.~For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG > 400 mg/dL; 7-9 units of insulin aspart
Study NCT02443402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental insulin (Insulin aspart)
Description: Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG >240 mg/dL will be given.~For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG > 400 mg/dL; 7-9 units of insulin aspart
Study NCT01407120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Beginnings Program
Description: A preventive intervention for divorced families.
Study NCT04396977 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Histamine 10 mg/ml skin prick
Description: Skin prick through 5 µL histamine diHCl (10 mg/ml)
Study NCT04396977 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placebo (saline) skin prick
Description: Skin prick through 5 µL saline (0.9% NaCl)
Study NCT00321516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: Tablets, Oral, 10, 20, or 30 mg (titrated), once daily, 14 days.
Study NCT01017497 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: PTV Diameter \< 2.0 cm receives 24 Gy; PTV Diameter 2.0-3.0 cm receives 18 Gy; PTV Diameter 3.1-4.0 cm receives 15 Gy;
Study NCT03651076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traxi panniculus retraction (Clinical Innovations, LLC)
Description: class I, FDA-exempt, commercially available for use in panniculus retraction during cesarean delivery or other laparotomy
Study NCT01986335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTP/HB/Hib Vaccine
Description: DPT/HB/Hib vaccine (Bio Farma)
Study NCT05855720 — intervention group
Intervention type: OTHER
Intervention: FIT model project
Description: Several statutory health insurance (SHI) funds have established contracts with hospitals for an alternative remuneration / financing of patients treated in the hospital (FIT hospital). Some of those contracts already started in 2013 and were prolonged. Some FIT contracts will start freshly (until June 2026). These contracts encourage FIT hospitals to test alternative treatment options for their patients (insured with the involved SHI funds), for example fewer inpatient and more outpatient treatment.
Study NCT03198221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely
Description: bowel preparation
Study NCT01986998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone 1250 mg/24h x3 days
Description: Oral Methylprednisolone 1.250 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (12 capsules of 100 mg and 1 capsule of 50 mg)
Study NCT01986998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Methylprednisolone 625 mg/24h x3 days
Description: Oral Methylprednisolone 625 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (6 capsules of 100 mg, 1 capsule of 25 mg and 6 capsules of placebo with the same appearance of capsules of 100 mg)
Study NCT02993809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-ECs and PRPE
Study NCT02993809 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BM-ECs
Study NCT03569059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dose-Matched Usual Physical Therapy Care
Description: Subjects will perform state-of-art usual physical/occupational care and 10 days of one additional hour of state-of-art usual inpatient and/or outpatient physical therapy/occupational therapy.
Study NCT03569059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delayed Robotic/VR Therapy (DVR)
Description: Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 31-60 days post stroke.
Study NCT03759184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-15
Description: Continuous intravenous (civ) Interleukin-15 (IL-15) at dose levels of 0.5,1 or 2 mcg/kg/day on days 1-5 of cycles 1-6
Study NCT03759184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-15
Description: Continuous intravenous (civ) Interleukin-15 (IL-15) at the maximum tolerated dose or the maximum administered dose of 2 mcg/kg/day on days 1-5 of cycles 1-6
Study NCT03667183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Specific postures in movement according to Pilates guidelines.
Study NCT03467399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus 7 Cochlear Implant System
Description: A new cochlear implant sound processor system.
Study NCT02544386 — intervention group
Intervention type: PROCEDURE
Intervention: MRI and 3D CT scan
Description: Measurement of bone microarchitecture at the legs and wrists by 3D CT Scan and measuring the proportion of fat in the imaging leg bone (MRI)
Study NCT03863002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell
Description: Mesenchymal stem cell transplantation via peripheral vein: 1.0-10x10\^5 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2, 3 weeks
Study NCT01736878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sorafenib
Study NCT01736878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study NCT01037114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
Study NCT01037114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: Engerix-B will be administered to subjects who are not seroprotected against hepatitis B.
Study NCT01037114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Havrix will be administered to subjects who are seronegative for anti-HAV antibodies.
Study NCT03625856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chlorella Vulgaris
Description: Chlorella capsules 1500 mg/day
Study NCT03625856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch 1500 mg
Study NCT00962611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (Aliqopa, BAY80-6946)
Description: BAY80-6946 given IV over 1 hour every week for three weeks with a one week break until progression or unacceptable toxicities develop.
Study NCT02514122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will receive a subcutaneous injection of ketamine (at a dose of 1mg/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
Study NCT02514122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients will receive a subcutaneous injection of saline (at a dose of 0.02cc/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
Study NCT01699191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Study NCT01699191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03377894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blunt uterine incision expansion
Description: blunt uterine incision expansion
Study NCT03377894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sharp uterine incision expansion
Description: sharp uterine incision expansion
Study NCT01082926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Given intratumorally
Study NCT01082926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given intratumorally
Study NCT01082926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT01082926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Optional correlative studies
Study NCT02355886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Given PO
Study NCT02355886 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT02355886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02355886 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02714062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po once daily
Study NCT02714062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521 Mid Dose
Description: po once daily
Study NCT02714062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521 Top Dose
Description: po once daily
Study NCT04106193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blended Facilitation
Description: Blended facilitation consists of an External Facilitator and Internal Facilitator to support adoption of intimate partner violence screening practices for WVs treated in primary care.
Study NCT04106193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation as usual
Description: Implementation as usual refers to traditional, site-initiated support for screening practices to detect intimate partner violence among WVs treated in primary care.
Study NCT04106193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toolkit
Description: All study arms will feature a toolkit meant to guide sites' adoption of intimate partner violence screening among WVs treated in primary care.
Study NCT03759184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous (IV) Obinutuzumab will be administered at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of cycle 1: then 1,000 mg on day 4 of each subsequent cycle
Study NCT05463822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transvaginal botulinum toxin A (BTA) injection
Description: Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
Study NCT02485977 — intervention group
Intervention type: DEVICE
Intervention: Magnetic resonance Imaging
Description: MRI study will be performed on 1.5 Tesla magnet, during the administration of Gadolinium
Study NCT00748072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDAVP
Description: 0.3 mcg/kg subcutaneous
Study NCT00748072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: saline solution 1 ml subcutaneous
Study NCT01931007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Aspirate Concentrate
Description: Autologous Bone marrow aspirate will be concentrated using Magellan Cell Separator and stem cell kit according to the Standard Operating Procedures is to be injected in the treatment knee. 5ml of treatment cells will be combined with 10 ml of previously separated platelet poor bone marrow plasma and used for injection under ultrasound guidance into one of the subject's painful knees.
Study NCT01931007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: Bacteriostatic 0.9% sodium chloride, preservative free manufactured by Hospira will be injected into the control knee.
Study NCT03125135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MightySat RX Pulse Oximeter Sensor
Description: Noninvasive pulse oximeter finger sensor.
Study NCT00947908 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hymenoptera venom
Description: Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
Study NCT04030091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 hours humulin R 100 IU/mL PIT
Description: PIT procedure: a venous catheter will be placed into one superficial vein at one arm, which will be connected to the insulin infusion pump and a glucose infusion pump via a three-way connector. Endothelial function will be measured by means of the Vendys 2 device. The blood glucose will be tested by means of a POCT meter and the CGM, and the PIT procedure will be started (10 pulses of 3 U of regular human insulin per hour). Blood glucose will be tested every 5 to 10 min and glucose infusion will be started once a drop in blood glucose is detected. Adjustment of glucose administration will be performed until a stable glucose value between 80 mg/dL to 160 mg/dL is reached. In parallel, endothelial function will be measured every 30 min. At the end of the PIT procedure, the venous catheter will be removed and the patient will be discharged until the next visit.
Study NCT04030091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 hours humulin R 100 IU/mL PIT
Description: As described for the Intervention 3 hours of pulsatile insulin infusion (PIT) with humulin R 100 IU/mL, the treatment duration is just one hour less.
Study NCT00859872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone oral solution
Description: risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral
Study NCT00859872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol
Description: haloperidol IM injection (5-20mg/d)
Study NCT03097107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 1 mg
Description: Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks
Study NCT03097107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 2 mg
Description: Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks
Study NCT03097107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 4 mg
Description: Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks
Study NCT03097107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomly assigned patients will receive placebo orally once each morning before breakfast for 12 weeks
Study NCT03474757 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Data will be extracted from July 2009 to the last available database extraction
Study NCT03184753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OC-IgT cells
Description: Autologous human OC-IgT cells.
Study NCT00905931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycopene
Description: 30 mg oral, daily, for 21 days
Study NCT00905931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: starch
Study NCT02821897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Target-controlled intravenous anaesthesia
Study NCT02821897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total anaesthesia
Study NCT02994810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding guidance
Description: Breastfeeding guidance
Study NCT03500003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute milk intake
Description: Food matrix: milk
Study NCT03500003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Yogurt intake
Description: Food matrix: yogurt
Study NCT00985894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Teledermatology Care
Description: Patients randomized to the intervention group will have their scheduled follow-up visits online via store and forward teledermatology.
Study NCT00985894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional in Office Care
Description: Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
Study NCT01457716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Single inhalation
Study NCT01457716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Single inhalation